Recent Updates
Recently added Catalysts
DTIL Positive Sentiment

Precision BioSciences to Report Second Quarter Results on August 1, 2024

Monday, July 29, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Precision BioSciences, a gene editing firm, will release its financial results for Q2 2024 on August 1, 2024. The company utilizes its proprietary ARCUS platform for developing in vivo gene editing therapies. This announcement reflects the company's ongoing commitment to transparency and innovation in the biopharma sector.
Price reaction · baseline $10 (2024-07-29 close) · hit after-hours · 3 other DTIL headline(s) in the window, move may be shared
day 0 close · peak
-4.5%

Market Sentiment Analysis

POSITIVE FACTORS

  • Precision BioSciences is advancing its gene editing technology.
  • The company is set to report financial results, indicating ongoing operations.
  • The use of the ARCUS platform highlights innovation in gene therapies.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+24%
120-day peak, hindsight
Typical move
4.8%
average across 2 past catalysts
Cash runway
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-T
Phase 1 · Advanced Lung Cancer

Full Press Release Details

DURHAM, N.C. –(BUSINESS WIRE)–Jul. 29, 2024– Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS ® platform to develop in vivo gene editing therapies, today announced that it will publish financial results for the second quarter 2024

Frequently Asked Questions

When will Precision BioSciences report its Q2 results?

Precision BioSciences will report its Q2 2024 results on August 1, 2024.

What platform does Precision BioSciences use?

The company utilizes its proprietary ARCUS platform for gene editing therapies.

What is the focus of Precision BioSciences?

Precision BioSciences focuses on developing in vivo gene editing therapies.

ShareAdd on Google
Tags: DTIL Viatris Investor Conferences Healthcare Precision BioSciences gene editing ARCUS platform financial results
Last updated: Jul 29, 2024

Biotech snapshot

Cash runway
$88M liquidity · $4M/mo burn
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-TPhase 1
Advanced Lung Cancer →

Catalyst track record

+24%
best trade around DTIL's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for DTIL.

See every catalyst's timing & PoA →